Information:
Error:
ID
34204
Description
RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab; ODM derived from: https://clinicaltrials.gov/show/NCT01943786
Link
https://clinicaltrials.gov/show/NCT01943786
Keywords
Versions (1)
- 1/15/19 1/15/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 15, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Colorectal Cancer Metastatic NCT01943786
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
diagnosis of stage iv colorectal adenocarcinoma.
boolean
ID.2
Item
patient ≥ 18 years of age.
boolean
ID.3
Item
ecog ps 0-1
boolean
ID.4
Item
life expectancy ≥ 6 months
boolean
ID.5
Item
candidate for first-line systemic chemotherapy according to regular clinical practice.
boolean
ID.6
Item
measurable disease.
boolean
ID.7
Item
wild-type kras
boolean
ID.8
Item
signed informed consent form.
boolean
ID.9
Item
patient who has received prior chemotherapy for metastatic crc, except for adjuvant treatment completed at least six months before entering study.
boolean
ID.10
Item
patient in whom there is a contraindication for the use of any of the drugs used in first-line treatment of colorectal cancer: 5-fluorouracil,, irinotecan or cetuximab
boolean